The stock may react positively to the turnaround in EBITDA and expense discipline, but the narrow gross margins and lack of strong 2026 growth guidance could cap upside. Watch for execution on positive operating cash flow in 2026 and any recovery in Middle East operations.
Price Chart
Executive Summary
IRIDEX Corporation reported strong Q4 and full-year 2025 results with 16% YoY revenue growth in the quarter and 8% for the year, driven by retina and glaucoma product sales. The company achieved positive adjusted EBITDA of $1.1 million for the year, a significant improvement from a $4.3 million loss in 2024, while reducing operating expenses by 22%. However, 2026 revenue guidance of $51M–$53M implies flat to slight growth, factoring in a complete exclusion of Middle East sales due to geopolitical disruptions.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $14.7M (+16% YoY), full-year 2025 revenue: $52.7M (+8% YoY)
- Net loss narrowed to $4.4M in 2025 from $8.9M in 2024; Q4 net loss improved to $0.2M from $0.8M
- Adjusted EBITDA turned positive at $1.1M in 2025 vs. -$4.3M in 2024
- Gross margin declined to 37% from 40% due to tariff impacts and inventory write-downs
- 2026 revenue guidance: $51M–$53M, implying flat to 5% growth on a pro forma basis excluding Middle East
- Operating expenses expected to remain lean at $19M–$19.5M in 2026
Financial Impact
Revenue growth of 8% and operating expense reduction of $6M drove improved cash flow and positive adjusted EBITDA. However, gross margin compression and cautious 2026 guidance limit upside.
Risk Factors
- Geopolitical disruptions in the Middle East could persist, affecting future revenue
- Gross margin pressure from tariffs and manufacturing costs may continue
- Adjusted EBITDA is non-GAAP; GAAP net loss remains significant at $4.4M
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263410 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 9w ago | 8-K | $0.7829 $0.6517 | ▲ +16.76% | ▲ +14.81% | $0.7550 (+3.56%) |
Aug 18, 2026 9w ago | Press Release | $0.7829 $0.6517 | ▲ +16.76% | ▲ +14.81% | $0.7550 (+3.56%) |
Jul 16, 2026 14w ago | 8-K | $0.9510 $0.8241 | ▲ +13.34% | ▲ +16.96% | $0.7550 (+20.61%) |
May 19, 2026 22w ago | 8-K | $1.00 $1.13 | ▲ +13.00% | ▲ +12.26% | $0.7550 (−24.50%) |
Apr 24, 2026 26w ago | DEFA14A | $1.08 $1.04 | ▼ −3.70% | ▼ −8.66% | $0.7550 (−30.09%) |
Apr 7, 2026 28w ago | Press Release | $1.03 $1.05 | ▲ +1.94% | ▼ −6.60% | $0.7550 (−26.70%) |
Mar 26, 2026 30w ago | Press Release | $0.9900 $1.08 | ▲ +9.09% | ▼ −3.65% | $0.7550 (−23.74%) |
Mar 12, 2026 32w ago | Press Release | $1.30 $1.03 | ▼ −20.77% | ▼ −24.36% | $0.7550 (−41.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers